Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Intramural Research Program, Bethesda, Maryland, USA.
Ann Rheum Dis. 2017 Dec;76(12):2009-2016. doi: 10.1136/annrheumdis-2017-211663. Epub 2017 Aug 9.
To determine trends in survival among adult and paediatric patients with systemic lupus erythematosus (SLE) from 1950 to the present.
We performed a systematic literature review to identify all published cohort studies on survival in patients with SLE. We used Bayesian methods to derive pooled survival estimates separately for adult and paediatric patients, as well as for studies from high-income countries and low/middle-income countries. We pooled contemporaneous studies to obtain trends in survival over time. We also examined trends in major causes of death.
We identified 125 studies of adult patients and 51 studies of paediatric patients. Among adults, survival improved gradually from the 1950s to the mid-1990s in both high-income and low/middle-income countries, after which survival plateaued. In 2008-2016, the 5-year, 10-year and 15-year pooled survival estimates in adults from high-income countries were 0.95, 0.89 and 0.82, and in low/middle-income countries were 0.92, 0.85 and 0.79, respectively. Among children, in 2008-2016, the 5-year and 10-year pooled survival estimates from high-income countries were 0.99 and 0.97, while in low/middle-income countries were 0.85 and 0.79, respectively. The proportion of deaths due to SLE decreased over time in studies of adults and among children from high-income countries.
After a period of major improvement, survival in SLE has plateaued since the mid-1990s. In high-income countries, 5-year survival exceeds 0.95 in both adults and children. In low/middle-income countries, 5-year and 10-year survival was lower among children than adults.
确定从 1950 年至今系统性红斑狼疮(SLE)成人和儿科患者的生存趋势。
我们进行了系统文献综述,以确定所有关于 SLE 患者生存的已发表队列研究。我们使用贝叶斯方法分别为成人和儿科患者、高收入国家和低收入/中等收入国家的研究得出汇总的生存估计值。我们汇总了同期研究,以获得随时间推移的生存趋势。我们还检查了主要死亡原因的趋势。
我们确定了 125 项成人患者和 51 项儿科患者的研究。在成人中,高收入和低收入/中等收入国家的生存率从 20 世纪 50 年代到 90 年代中期逐渐提高,之后生存率趋于平稳。在 2008-2016 年期间,高收入国家成人患者的 5 年、10 年和 15 年汇总生存率分别为 0.95、0.89 和 0.82,低收入/中等收入国家分别为 0.92、0.85 和 0.79。在儿童中,在 2008-2016 年期间,高收入国家的 5 年和 10 年汇总生存率分别为 0.99 和 0.97,而低收入/中等收入国家分别为 0.85 和 0.79。随着时间的推移,高收入国家成人和儿童研究中 SLE 导致的死亡比例有所下降。
在经历了一段重大改善之后,SLE 的生存率自 20 世纪 90 年代中期以来趋于平稳。在高收入国家,成人和儿童的 5 年生存率均超过 0.95。在低收入/中等收入国家,儿童的 5 年和 10 年生存率均低于成人。